Could a common diabetes pill protect your heart?
NCT ID NCT07614230
First seen Jun 02, 2026
Summary
This study tests whether dapagliflozin, a diabetes medication, can slow or reverse plaque buildup in the heart arteries of people with type 2 diabetes. About 144 adults with stable heart disease will take either the drug plus standard care or standard care alone for 18 months. Researchers will use CT scans to measure changes in plaque and inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Medical Center of Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Sixth Medical Center of Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin
What this could lead to
If successful, this could show that dapagliflozin helps slow or stop plaque buildup in heart arteries, reducing heart attack risk in people with type 2 diabetes.
What could go wrong
This is a relatively small, early-phase trial (144 participants) testing a secondary effect of an existing drug. The results may not confirm benefit, and side effects like dehydration or infections are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.